公开(公告)号：US20090226407A9

公开(公告)日：2009-09-10

申请号：US10692724

申请日：2003-10-27

申请人： Joseph Loscalzo ,  Joseph Vita ,  Michael Loberg ,  Manuel Worcel

发明人： Joseph Loscalzo ,  Joseph Vita ,  Michael Loberg ,  Manuel Worcel

IPC分类号： A61K38/43 ,  A01N43/04

CPC分类号： A61K31/135 ,  A61K9/0056 ,  A61K9/7023 ,  A61K31/19 ,  A61K31/34 ,  A61K31/355 ,  A61K31/415 ,  A61K31/495 ,  A61K31/50 ,  A61K31/535 ,  A61K45/06 ,  A61K2300/00

摘要： The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, and optionally at least one compound used to treat cardiovascular diseases and/or at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The vascular diseases characterized by nitric oxide insufficiency include a cardiovascular disease and a disease resulting from oxidative stress.

摘要翻译： 本发明提供治疗和/或预防以一氧化氮不足为特征的血管疾病的方法，其通过施用治疗有效量的至少一种亚硝化血管紧张素转换酶抑制剂，亚硝化β-肾上腺素能阻断剂，亚硝化胆固醇降低剂，亚硝化钙通道阻断剂，亚硝化 内皮素拮抗剂，亚硝化血管紧张素II受体拮抗剂，亚硝化肾素抑制剂和任选的至少一种用于治疗心血管疾病的化合物，和/或至少一种抗氧化剂或其药学上可接受的盐，和/或至少一种可以转移的化合物 或释放一氧化氮，提高内源性内源性舒张因子水平，刺激一氧化氮的内源性合成，或是一氧化氮合成酶的底物。 抗氧化剂可优选为肼屈嗪化合物或其药学上可接受的盐。 捐赠，转移或释放一氧化氮的化合物提高内源性内皮衍生的松弛因子水平，刺激一氧化氮的内源性合成，或者是一氧化氮合酶的底物可优选为硝酸异山梨酯和/或一硝酸异山梨酯。 以一氧化氮不足为特征的血管疾病包括心血管疾病和由氧化应激引起的疾病。

公开(公告)号：US20070072927A1

公开(公告)日：2007-03-29

申请号：US11463881

申请日：2006-08-10

申请人： Joseph Vita ,  Bruce Ames ,  Benjamin Treadwell

发明人： Joseph Vita ,  Bruce Ames ,  Benjamin Treadwell

IPC分类号： A61K31/4188 ,  A61K31/385 ,  A61K31/22 ,  A61K31/205

CPC分类号： A61K31/22 ,  A61K31/205 ,  A61K31/385 ,  A61K31/4188 ,  A61K2300/00

摘要： In a method of treating hypertension in individuals suffering therefrom, the method includes administering to said individuals an effective amount of carnitine and an effective amount of lipoic acid. A method of treating hypertension in individuals suffering therefrom includes administering twice a day a combination of 500 mg carnitine, 200 mg lipoic acid and optionally 100 micrograms of biotin. A method of treating hypertension in individuals with systolic blood pressure above about 135 mmHg includes administering a combination of carnitine, lipoic acid and optionally biotin.

摘要翻译： 在治疗患有高血压的个体的方法中，所述方法包括向所述个体施用有效量的肉碱和有效量的硫辛酸。 治疗患有高血压的个体的方法包括每天两次给予500mg肉碱，200mg硫辛酸和任选的100微克生物素的组合。 收缩压高于约135mmHg的个体治疗高血压的方法包括给予肉碱，硫辛酸和任选的生物素的组合。